# OnCo record cytospire-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/cytospire-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "cytospire-therapeutics" ;
  schema:name "Cytospire Therapeutics"@en ;
  schema:description "Cytospire Therapeutics makes antibodies that pull a particular family of immune cells, gamma delta T cells, onto cancer cells so they kill them. Its first medicine, for bowel, head and neck and lung cancers that carry the EGFR protein, was being prepared for its first human trial in 2026."@en ;
  schema:url <https://onco.cc/companies/cytospire-therapeutics/>, <https://www.cytospire.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.cytospire.com/>, <https://www.cytospire.com/cytospire-therapeutics-announces-oversubscribed-61-million-83m-series-a-financing-to-advance-pipeline-of-first-in-class-pan-gamma-delta-t-cell-engagers-into-clinical-trials-for-the-treatment-of-can/>, <https://www.biopharmadive.com/news/cytospire-gamma-delta-t-cell-engager-series-a/819234/> ;
  schema:addressCountry "GB" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/egfr/> .